These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 37631374)

  • 21. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
    Tarantino P; Carmagnani Pestana R; Corti C; Modi S; Bardia A; Tolaney SM; Cortes J; Soria JC; Curigliano G
    CA Cancer J Clin; 2022 Mar; 72(2):165-182. PubMed ID: 34767258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bystander effect of antibody-drug conjugates: fact or fiction?
    Giugliano F; Corti C; Tarantino P; Michelini F; Curigliano G
    Curr Oncol Rep; 2022 Jul; 24(7):809-817. PubMed ID: 35305211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
    Shih CH; Lin YH; Luo HL; Sung WW
    Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS).
    Mao K; Chen P; Sun H; Zhong S; Zheng H; Xu L
    Front Pharmacol; 2024; 15():1425617. PubMed ID: 39228525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.
    Koukoutzeli C; Trapani D; Ascione L; Kotteas E; Marra A; Criscitiello C; Curigliano G
    Clin Med Insights Oncol; 2024; 18():11795549241260418. PubMed ID: 38894701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Nerone M; Grande MD; Sessa C; Colombo I
    Explor Target Antitumor Ther; 2022; 3(2):149-171. PubMed ID: 36046840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Coleman N; Yap TA; Heymach JV; Meric-Bernstam F; Le X
    NPJ Precis Oncol; 2023 Jan; 7(1):5. PubMed ID: 36631624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
    Dias E Silva D; Andriatte GM; Pestana RC
    Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.
    Schöffski P; Wang CC; Schöffski MP; Wozniak A
    Oncol Res Treat; 2024; 47(1-2):18-41. PubMed ID: 38016427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
    High P; Guernsey C; Subramanian S; Jacob J; Carmon KS
    Pharmaceutics; 2024 Jul; 16(7):. PubMed ID: 39065587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
    Peng H
    Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
    Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
    Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
    Nelson BE; Meric-Bernstam F
    Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.